News
ESALY
61.65
NaN%
--
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Eisai and Biogen's Leqembi is the first drug shown to slow Alzheimer’s progression. The drug faces skepticism among some doctors. Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and risks of the drug.
Benzinga · 04/24 18:23
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Biogen Inc and Eisai Co Ltd faced a setback as the oral explanation of lecanemab was postponed. The delay has implications for the review process of a pivotal drug currently under evaluation by the European Medicines Agency. The Oral Explanation was slated for March 19.
Benzinga · 03/22 17:44
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
The FDA is expected to delay its decision on Eli Lilly's Alzheimer's drug. The drug, donanemab, would compete with Biogen’s Leqembi. The FDA will convene an advisory committee to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial.
Benzinga · 03/08 13:58
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, down 6% Y/Y. Biogen's partner, Eisai Co Ltd, has faced a delay in reaching the 10,000-patient mark for Leqembi. Baird analyst has lowered the price target to $316 from $333.
Benzinga · 02/14 20:11
Why Is Biogen Stock Trading Lower On Tuesday?
Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, down 6% Y/Y and 5% at constant currency. European Commission approved Skyclarys for Friedreich's ataxia on Tuesday.
Benzinga · 02/13 17:42
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
Washington University School of Medicine pioneered blood tests capable of detecting sticky amyloid plaques, a key Alzheimer's indicator. Current blood tests for Alzheimer’s lack sufficient regulation, and none have received FDA approval. Blood tests offer a quick and less invasive way to identify patients and determine eligibility for emerging drugs.
Benzinga · 01/12 18:17
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
Leap-001 trial of keytruda and lenvima did not meet primary endpoints. Merck & co and eisai failed to meet endpoints of overall survival and progression-free survival for patients with endometrial carcinoma. The trial included patients with advanced or recurrent endometriosis.
Benzinga · 12/08/2023 13:26
Alzheimer's Disease Drug Development: Another Lost Year
Investing in most current alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of alzheimer's disease over the short term. The fda's approval of anti-amyloid drug leqembi was a failure.
Seeking Alpha · 12/05/2023 08:58
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Benzinga · 10/11/2023 18:27
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Benzinga · 10/10/2023 16:35
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Benzinga · 09/25/2023 14:41
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Benzinga · 09/22/2023 14:21
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Benzinga · 08/25/2023 15:58
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
Benzinga · 07/07/2023 17:25
Catalyst Pharmaceuticals: Cheap For A Reason
Seeking Alpha · 07/03/2023 10:49
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
Benzinga · 06/14/2023 17:52
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, European Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories
Benzinga · 06/13/2023 14:02
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Benzinga · 06/13/2023 12:30
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
Benzinga · 06/12/2023 18:01
Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
Benzinga · 06/12/2023 11:00
More
Webull provides a variety of real-time ESALY stock news. You can receive the latest news about Eisai through multiple platforms. This information may help you make smarter investment decisions.
About ESALY
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.